Chi-Med revenue ahead, but investments kill most income
2nd Aug 2016 16:19
(ShareCast News) - Hutchison China MediTech reported its interim results for the six months to 30 June on Tuesday, with group revenue up 27% to $104.5m, from $82.5m. The AIM-traded firm said net income attributable to Chi-Med was $0.5m, significantly down from $15.9m a year ago, reflecting a sharp i
Read moreChi-Med expands TATTON Phase II trial
20th Jun 2016 15:26
(ShareCast News) - Healthcare group Hutchison China MediTech (Chi-Med) announced on Monday the start of a Phase II expansion of its ongoing TATTON trial. The AIM-traded firm said the TATTON trial is evaluating the selective c-Met inhibitor savolitinib in epidermal growth factor receptor (EGFR) mutan
Read moreChi-Med launches fruquintinib trial in China
13th May 2016 16:27
(ShareCast News) - Hutchison China MediTech announced on Friday that it has completed patient enrolment of FRESCO, its Phase III trial of fruquintinib in third-line locally advanced or metastatic colorectal cancer in China. The AIM-traded company said more than 300,000 new cases of CRC were diagnose
Read moreDirector dealing: Somero CEO sells half stake for tax bill
21st Mar 2016 13:19
(ShareCast News) - Somero Enterprises chief executive Jack Cooney and his wife sold off over £2m of the company's shares, reportedly in order to satisfy a US tax bill. The Cooney's sold 1.4m shares, representing 2.49% of the current issued share capital of the company and approximately half of their
Read moreHutchison China first-half profit drops as research spending rises
28th Jul 2015 11:26
(ShareCast News) - Healthcare group Hutchison China MediTech posted a drop in first-half pre-tax profit as it invested more heavily in research and development. For the six months ended 30 June, pre-tax profit came in at $3.9m from $7.3m as a higher spend in R&D and cost of sales offset an increase
Read moreHutchison China Meditech chairman buys £0.8m worth of shares
8th Apr 2015 15:36
Hutchison China MediTech revealed on Wednesday its chairman and secretary bought some shares in the company. Executive director and chairman Simon To on Tuesday purchased 48,000 shares for 1385p each, spending £664,800 in the transaction. Furthermore, non-executive director and secretary Edith Shih
Read moreTo dips in at Hutchinson China-Meditech
20th Nov 2014 15:26
Since falling below 40p in the height of the financial crisis, shares in Hutchison China MediTech (Hutchison Chi-Med) have climbed and climbed and climbed more than 3,000% but executive chairman Simon To seems to believe they can ascend yet higher. To, the founder and managing director of the tradit
Read moreWednesday broker round-up UPDATE
30th Jul 2014 09:50
Antofagasta: Westhouse Securities downgrades from add to neutral with a target price of 885p. Investec places its target price (prev.: 690p) under review, while keeping its sell recommendation. Aureus Mining: FinnCap lowers target price from 66p to 62p maintaining a buy recommendation. British Ame
Read moreMonday broker round-up UPDATE
19th May 2014 07:55
Alent: Numis moves target price from 330p to 340p upgrading to add. AVEVA Group: Westhouse Securities initiates with a target price of 2260p and a buy recommendation. Bovis Homes Group: Deutsche Bank shifts target price from 1039p to 1042p and stays with its buy recommendation. Brown (N) Group: J
Read moreWednesday broker round-up UPDATE
2nd Apr 2014 08:48
Aberdeen Asset Management: Canaccord Genuity reduces target price from 540p to 460p, while its buy recommendation is kept. Anglo American: JP Morgan ups target price from 1260p to 1300p, while leaving its underweight rating unchanged. Aviva: JP Morgan raises target price from 528p to 570p maintain
Read moreFriday broker round-up UPDATE
14th Mar 2014 09:07
Barclays: Nomura reduces target price from 305p to 285p staying with its buy recommendation. Investec lowers target price from 305p to 295p and keeps its buy recommendation. Ferrexpo: Westhouse Securities increases target price from 190p to 220p and reiterates a buy recommendation. F&C Asset Manag
Read moreHutchison China MediPharma director takes stake in company
16th Oct 2013 16:19
Edith Shih, a Non-Executive Director and Company Secretary of Hutchison China MediPharma, acquired 20,000 shares in the firm, which is the holding company of a healthcare group based primarily in China and focused on researching, developing, manufacturing and selling pharmaceuticals and health orien
Read moreHutchison signs Chinese licensing and marketing deal with Eli Lilly
9th Oct 2013 10:58
A business majority owned by Hutchison China MediPharma has entered into a licensing, co-development, and commercialisation agreement in China with US pharmaceutical manufacturer Eli Lilly. The agreement relates to Fruquintinib, an oncology therapy for the potential treatment of various types of s
Read moreWednesday broker round-up UPDATE
9th Oct 2013 07:57
Air Partner: Liberum Capital initiates with a target price of 555p and a buy recommendation. Alent: Credit Suisse moves target price from 420p to 430p and keeps an outperform rating. AZ Electronic Materials: Credit Suisse revises target price from 350p to 330p, while staying with its neutral ratin
Read moreInmarsat Chairman sells 1.4m pounds-worth of shares
8th Aug 2013 15:57
The Chairman of Inmarsat made 1.4m pounds this week by selling around a fifth of his stake in the satellite operator, the firm announced on Thursday. Andrew Sukawaty, who joined the firm 10 years ago, sold 200,000 shares in the company at a price of 700p each, taking advantage of the stock's 20% ri
Read more